Artiklar och insikter för Curasight

Curasight navigates a challenging 2024 with strategic partnerships and clinical advancements.

Curasight announces a successful rights issue to strengthen its financial base for upcoming clinical milestones.

Curasight announces a rights issue aiming to raise DKK 100 million, bolstering its innovative cancer treatment technologies.

Curasight's shareholders approve key resolutions to expand share capital authorization, setting the stage for strategic growth.

Curasight föreslår att utöka styrelsens befogenheter för att öka aktiekapitalet och utfärda teckningsoptioner.

Curasight announces a significant rights issue to support its innovative cancer diagnostics and treatment platforms.

Curasight har offentliggjort viktiga datum för 2025, inklusive deras Årsstämma och rapporteringsschema.

Curasight fortsätter att utveckla sina innovativa plattformar trots ekonomiska utmaningar.

Curasight has announced the schedule for its 2025 Annual General Meeting and key financial reports, setting the stage for an eventful year.